Matinas BioPharma Holdings MTNB
NYSE MTNB
$2.61 +0.17 (+6.97%)
At close: Oct 2, 2026 · 4:00 PM EDT

Matinas BioPharma Holdings (MTNB) Gains from Sales and Divestitures (2025 - 2026)

Updated

Matinas BioPharma Holdings (MTNB) reported Gains from Sales and Divestitures of -$138,000 for Q2 2026, compared with $110,000 a year earlier.

Analysis

Matinas BioPharma Holdings (MTNB) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Matinas BioPharma Holdings' Gains from Sales and Divestitures came in at -$101,000; for FY2025, it came in at $37,000.

  • By year, Gains from Sales and Divestitures came in at -$1,000 in FY2023, -$2,000 in FY2022 and -$2,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Matinas BioPharma Holdings 16.72 Mn 4.13 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -138,000.00
Dec 31, 2025 -73,000.00
Jun 30, 2025 110,000.00
API Access

Matinas BioPharma Holdings Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=MTNB&period=max&api_key=YOUR_API_KEY